ClinicalTrials.gg
CompletedNCT04294251Updated Nov 30, 2022

Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy

A Phase 3 interventional study of DWP450 and Placebo in Benign Masseteric Hypertrophy, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-30.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This Study is A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy

02

Conditions studied

  • Benign Masseteric Hypertrophy
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subject over 18 years of age and written is obtained.
  2. Subject with Benign Masseter Hypertrophy.
  3. Subject who has Bisymmetry of masseter at visual assessment.
  4. Subjects who meets thickness of Masseter muscle by ultrasonography.
  5. Subjects who can and will comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of Myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function.
  2. Subject who got any facial aesthetic procedure (e.g. surgery, laser, thread treatment etc.) in lower facial area within 52 weeks prior to the study entry.
  3. Subject who had previously received botulinum toxin within 12 weeks prior to the study entry.
  4. Subject with known to botulinum toxin.
  5. Subject who are pregnant or lactating or found pregnancy though the urine or sebum test or disagreed to avoid pregnancy during study period.
  6. Subjects who are not eligible for this study at the discretion of the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    DWP450

    Drug: DWP450

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugDWP450

    Botulinum toxin type A(DWP450) will be administered intramuscularly to the bilateral masseter muscles on Day 1.

  • DrugPlacebo

    Placebo(Normal Saline) will be administered intramuscularly to the bilateral masseter muscles on Day 1.

06

What researchers measure

Primary outcomes

  1. Change from baseline in masseter muscle thickness

    Change from baseline in masseter muscle thickness by Ultrasonography

    Time frame: 12 weeks

Secondary outcomes

  1. Change from baseline in masseter muscle thickness

    Change from baseline in masseter muscle thickness by Ultrasonography

    Time frame: 24 weeks

  2. Change from baseline in lower face volume

    Change from baseline in lower face volume by 3D digital imaging

    Time frame: 24 weeks

  3. Overall satisfaction of subject: questionnaire

    Subject satisfaction assessment using a scale ranging from very dissatisfied to very satisfied by questionnaire

    Time frame: 24 weeks

07

Study locations

1 site
  • Chung-ang University Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Jan 2021, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2020
First posted
Mar 4, 2020
StartActual
Mar 4, 2020
Primary completionActual
Jan 7, 2021
CompletionActual
Aug 10, 2021
Last update
Nov 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04294251
Responsible party
Sponsor
First posted
Mar 4, 2020
Start date
Mar 4, 2020
Primary completion
Jan 7, 2021
Completion
Aug 10, 2021
Last update
Nov 30, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prabotulinumtoxin A

Start the discussion